Literature DB >> 23937530

Dose-dependent inhibitory effects of proton pump inhibitors on human osteoclastic and osteoblastic cell activity.

João Costa-Rodrigues1, Sara Reis, Sónia Teixeira, Sandra Lopes, Maria H Fernandes.   

Abstract

Proton pump inhibitors (PPIs), a class of molecules that are used to decrease gastric acid production, might have adverse effects on bone metabolism. The aim of this study was to characterize the concentration-dependent and time-dependent effects of three PPIs (omeprazole, esomeprazole, and lansoprazole) on human osteoclast precursor cells isolated from peripheral blood, and on human mesenchymal stem cells (osteoblast precursors). Cell cultures were characterized for total protein content, apoptosis, and several osteoclastic/osteoblastic features, and also for the involvement of some intracellular signaling pathways. PPIs caused a dose-dependent decrease in cellular density, which correlated with an increase in the apoptosis rate, effects that became statistically significant at concentrations ≥ 10(-5) m. They also inhibited phenotype-related gene expression and functional parameters. For both cell types, cellular function, i.e. osteoclastic resorption and the formation of mineralized deposits by osteoblastic cells, was more affected than proliferation-related parameters. The three PPIs showed similar qualitative and quantitative effects, but displayed some differences in the underlying intracellular signaling pathways. These results suggest that PPIs might have a direct deleterious effect on bone cells, with the possibility of decreased bone turnover.
© 2013 FEBS.

Entities:  

Keywords:  bone metabolism; intracellular signaling pathways; osteoblastic cells; osteoclastic cells; proton pump inhibitors

Mesh:

Substances:

Year:  2013        PMID: 23937530     DOI: 10.1111/febs.12478

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  34 in total

1.  Proton pump inhibitors and fracture: do they do what it says on the tin?

Authors:  O F Uzoigwe
Journal:  Osteoporos Int       Date:  2016-02-04       Impact factor: 4.507

Review 2.  Use of proton pump inhibitors in dialysis patients: a double-edged sword?

Authors:  Geoffroy Desbuissons; Lucile Mercadal
Journal:  J Nephrol       Date:  2020-07-24       Impact factor: 3.902

3.  Long-Term Proton Pump Inhibitor Use Is Not Associated With Changes in Bone Strength and Structure.

Authors:  Laura E Targownik; Andrew L Goertzen; Yunhua Luo; William D Leslie
Journal:  Am J Gastroenterol       Date:  2016-11-15       Impact factor: 10.864

4.  Proton Pump Inhibitors, Histamine-2 Receptor Antagonists, and Hip Fracture Risk among Patients on Hemodialysis.

Authors:  Chandan Vangala; Jingbo Niu; Colin R Lenihan; William E Mitch; Sankar D Navaneethan; Wolfgang C Winkelmayer
Journal:  Clin J Am Soc Nephrol       Date:  2018-09-27       Impact factor: 8.237

5.  Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study.

Authors:  S-M Lin; S-H Yang; C-C Liang; H-K Huang
Journal:  Osteoporos Int       Date:  2017-10-14       Impact factor: 4.507

6.  Proton pump inhibitors' use and risk of hip fracture: a systematic review and meta-analysis.

Authors:  Salman Hussain; Ali Nasir Siddiqui; Anwar Habib; Md Sarfaraj Hussain; Abul Kalam Najmi
Journal:  Rheumatol Int       Date:  2018-08-29       Impact factor: 2.631

7.  Proton pump inhibitors and osteoporosis risk: exploring the role of TRPM7 channel.

Authors:  Bhargavi V Desai; Misbah N Qadri; Bhavin A Vyas
Journal:  Eur J Clin Pharmacol       Date:  2021-10-29       Impact factor: 2.953

Review 8.  Do proton pump inhibitors affect the biomechanical efficiency of implant?- a systematic review.

Authors:  Varsha Verma
Journal:  J Oral Biol Craniofac Res       Date:  2022-08-17

9.  Proton pump inhibitors and fracture risk. The HUNT study, Norway.

Authors:  M Hoff; E Skovlund; S Skurtveit; H E Meyer; A Langhammer; A J Søgaard; U Syversen; S Forsmo; B Abrahamsen; B Schei
Journal:  Osteoporos Int       Date:  2019-11-18       Impact factor: 4.507

10.  Load-sharing through elastic micro-motion accelerates bone formation and interbody fusion.

Authors:  Eric H Ledet; Glenn P Sanders; Darryl J DiRisio; Joseph C Glennon
Journal:  Spine J       Date:  2018-02-13       Impact factor: 4.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.